ArticleGastroenterology & hepatology2025
Once-Monthly Efimosfermin Alfa for Up to 48 Weeks in MASH With F2/F3 Fibrosis: Results From a Phase 2, Open-Label Extension Study.
No numbers read from the abstract.
1 paper cites it
this papercites it
ArticleGastroenterology & hepatology2025
No numbers read from the abstract.